Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Researchers identify a powerful combination of antivirals to treat COVID-19

by Medical Finance
in Coronavirus
Study identifies cellular receptors for alphaviruses shared across mosquitoes, humans, and animals
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Researchers at the University of Maryland School of Medicine (UMSOM) and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19. The researchers showed that combining the experimental drug brequinar with either of the two drugs already approved by the U.S. Food and Drug Administration for emergency use, remdesivir or molnupiravir, inhibited growth of the SARS-CoV-2 virus in human lung cells and in mice. Their findings suggest that these drugs are more potent when used in combination than individually.

The study was published on February 7, 2022, in Nature.

We demonstrated that brequinar and molnupiravir work better together than either drug alone in our mouse model of COVID-19. As the virus continues to spread and mutate, we want drugs that are accessible, easy to administer, and effective against the current and future variants.”


Matthew Frieman, PhD, Co-Principal Investigator, Associate Professor Microbiology and Immunology, and Member of the Center for Pathogen Research at UMSOM

Though they have not yet been tested in clinical trials, the combinations of treatments identified in their study have the potential to substantially reduce hospitalizations and deaths, said Co-Principal Investigator Sara Cherry, PhD, a professor of Pathology and Laboratory Medicine at the University of Pennsylvania.

There remains an urgent need for therapeutics to treat COVID-19, which has been amplified by emerging threats of new variants that may evade vaccines. In response to this demand, Dr. Cherry, and her team, along with David Schultz, PhD, Technical Director of the Penn High-Throughput Screening Core, screened 18,000 FDA-approved drugs in search of those with antiviral activity using SARS-CoV-2 infected in human lung cells, as they are a major target for the virus.

The researchers identified 122 drugs that showed antiviral activity against the coronavirus. One drug identified was remdesivir, which has been FDA-approved to treat COVID-19 infection via injection through an IV, and another was molnupiravir, which comes in a pill that was authorized for use in December. These drugs look similar to one of the four RNA-building blocks that comprise the genetic sequence of the virus. Remdesivir gets incorporated into the RNA when the virus replicates and essentially stops it from making copies of itself. Molnupiravir gets incorporated into the replicating virus and causes its genetic sequence to change -; essentially mutating the virus so it cannot grow.

Another category of drug candidates they identified prevents the virus from making the RNA building blocks the virus needs to replicate. One of these included the experimental drug brequinar, which is currently being tested in clinical trials as a COVID-19 treatment and as part of a potential combination therapy for cancer.

The team hypothesized that combining brequinar with one of fake RNA building block drugs, such as remdesivir or molnupiravir, could work synergistically to create a more potent effect against the virus.

It was through the Bill and Melinda Gates Foundation that Dr. Cherry’s program manager suggested her team connect with Dr. Frieman’s group as his laboratory has developed a mouse model for COVID-19. Together, the researchers tested the drugs in lung cells and in mice finding that these combinations were highly effective against multiple variants of the coronavirus.

Also, the research team found that paxlovid -; another antiviral pill recently authorized -; could be combined with remdesivir or molnupiravir for an “additive” effect against the virus.

“Identifying combinations of antivirals is important, not only to increase the drugs’ potency against the coronavirus, but combining these drugs also reduces the risk of resistance,” said Dr. Cherry.

The team is now in the process of testing the drugs against Omicron. They will continue to explore effective combinations of already available drugs against SARS-CoV-2.

The next step for the drug combinations tested in this study is for the Gates Foundation to move these therapeutics forward in clinical trials.

SARS-CoV-2, the virus that causes COVID-19, has infected 382 million people and led to 5 million deaths worldwide.

“We have already lost 5 million people worldwide to the COVID pandemic, and even though we have vaccines and therapies, we are still losing people. Because of this it is of utmost importance that we continue to explore additional and more effective treatment options and antiviral medications,” said Dean E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor at the University of Maryland School of Medicine.

Source:

University of Maryland School of Medicine

Journal reference:

Schultz, D.C., et al. (2022) Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature. doi.org/10.1038/s41586-022-04482-x.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: A method for variant agnostic detection of SARS-CoV-2, rapid monitoring of circulating variants, detection of mutations of biological significance, and early detection of emergent variants such as Omicron. Image Credit: Lightspring/Shutterstock

New method for monitoring circulating SARS-CoV-2 variants and detecting new ones

by Medical Finance
May 20, 2022
0

After more than two years of the coronavirus disease (COVID-19) pandemic, there is still a constant threat of evolving strains...

Study: Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. Image Credit: PhotobyTawat/Shutterstock

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers investigated the impact of the fourth...

Study: Egg-derived anti-SARS-CoV-2 immunoglobulin Y (IgY) with broad variant activity as intranasal prophylaxis against COVID-19: preclinical studies and randomized controlled phase 1 clinical trial. Image Credit: NIAID

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

by Medical Finance
May 20, 2022
0

Coronavirus disease 2019 (COVID-19), caused by the rapid outbreak of severe acute respiratory disease coronavirus-2 (SARS-CoV-2), has claimed more than...

Study: Engineering SARS-CoV-2 Neutralizing Antibodies for Increased Potency and Reduced Viral Escape. Image Credit: LuXiFeR Bowlo / Shutterstock.com

Engineering higher affinity SARS-CoV-2 antibodies

by Medical Finance
May 20, 2022
0

With the widespread and rapid transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of hospitalizations is...

Study: Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose. Image Credit: peterschreiber.media / Shutterstock.com

Third dose of mRNA COVID vaccine induces strong immunity in older adults

by Medical Finance
May 20, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen has been circulating since the end of 2019, causing the ongoing...

(A) Schematic of the physical changes that take place when an airborne aqueous droplet equilibrates to the surrounding relative humidity. On the left (blue box) the particle is an aqueous homogenous sphere. As the particle equilibrates to a sub-saturated RH, low-solubility solutes can precipitate inclusions within the droplet (yellow box). At a sufficiently low RH, the dominant solute (NaCl) can crystallize causing the particle to effloresce (black box). (B) Schematic of the CELEBS technique. Virus-containing particles are levitated under controlled conditions and then deposited into media which is then plated onto a cell culture. By enumerating the cytopathic effect from that deposition, the amount of virus present can be quantified. (C) Schematic of the CK-EDB technique. Particles generated by the same droplet dispensers used in CELEBS are levitated under controlled conditions in the path of a laser. The physical changes that take place in that particle are studied through analysis of the light scattered by that particle.

Airborne decay of SARS-CoV-2 occurs within minutes

by Medical Finance
May 20, 2022
0

Understanding the factors that influence the airborne survival of viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in...

Next Post
Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Researchers show the feasibility of a comprehensive sequencing approach in pediatric and young adult cancers

NPS

Tackling the Global Issue of New Psychoactive Substances

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes. Image Credit: Iurii Kachkovskyi/Shutterstock
    Researchers construct models to predict SARS-CoV-2 mutable and constrained positions
  • Study: An intranasal nanoparticle STING agonist has broad protective immunity against respiratory viruses and variants. Image Credit: pinkeyes/Shutterstock
    Intranasal nanoparticle STING agonist with immunoantiviral activity against SARS-CoV-2 variants
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply